Preservation of neuronal function as measured by clinical and MRI endpoints in relapsing-remitting multiple sclerosis: how effective are current treatment strategies?

References

• Kutzelnigg A, Lassmann H. Pathology of multiple sclerosis and related inflammatory demyelinating diseases. Handb Clin Neurol. 2014;122:15–58.
   PubMedGoogle Scholar
• Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2017. DOI:10.1016/s1474-4422(17)30470-2.
   Web of Science ®Google Scholar
• Wiendl H, Elger C, Foerstl H, et al. Gaps between aims and achievements in therapeutic modification of neuronal damage (“neuroprotection”). Neurotherapeutics. 2015;12:449–454.
   PubMed Web of Science ®Google Scholar
• Zipp F, Gold R, Wiendl H. Identification of inflammatory neuronal injury and prevention of neuronal damage in multiple sclerosis hope for novel therapies? JAMA Neurol. 2013;70:1569–1574.
   PubMed Web of Science ®Google Scholar
• Luessi F, Siffrin V, Zipp F. Neurodegeneration in multiple sclerosis: novel treatment strategies. Expert Rev Neurother. 2012;12:1061–1076.
   PubMed Web of Science ®Google Scholar
• Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83:278–286.
   PubMed Web of Science ®Google Scholar
• Miller D, Barkhof F, Montalban X, et al. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol. 2005;4:281–288.
   PubMed Web of Science ®Google Scholar
• Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69:292–302.
   PubMed Web of Science ®Google Scholar
• Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat Rev Immunol. 2015;15:545–558.
   PubMed Web of Science ®Google Scholar
• Fisher E, Lee J-C, Nakamura K, et al. Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann Neurol. 2008;64:255–265.
   PubMed Web of Science ®Google Scholar
• Larochelle C, Uphaus T, Prat A, et al. Secondary progression in multiple sclerosis: neuronal exhaustion or distinct pathology? Trends Neurosci. 2016;39:325–339.
   PubMed Web of Science ®Google Scholar
• Correale J, Gaitan MI, Ysrraelit MC, et al. Progressive multiple sclerosis: from pathogenic mechanisms to treatment. Brain. 2017;140:527–546.
   PubMed Web of Science ®Google Scholar
• Amato MP, Derfuss T, Hemmer B, et al. Environmental modifiable risk factors for multiple sclerosis: report from the 2016 ECTRIMS focused workshop. Mult Scler J. 2017. DOI:10.1177/1352458516686847.
   Google Scholar
• Baranzini SE, Khankhanian P, Patsopoulos NA, et al. Network-based multiple sclerosis pathway analysis with GWAS data from 15,000 cases and 30,000 controls. Am J Hum Genet. 2013;92:854–865.
   PubMed Web of Science ®Google Scholar
• Beecham AH, Patsopoulos NA, Xifara DK, et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet. 2013;45:1353–1360.
   PubMed Web of Science ®Google Scholar
• Lill CM, Schjeide B-M-M, Graetz C, et al. MANBA, CXCR5, SOX8, RPS6KB1 and ZBTB46 are genetic risk loci for multiple sclerosis. Brain. 2013;136:1778–1782.
   PubMed Web of Science ®Google Scholar
• Moutsianas L, Jostins L, Beecham AH, et al. Class II HLA interactions modulate genetic risk for multiple sclerosis. Nat Genet. 2015;47:1107–1113.
   PubMed Web of Science ®Google Scholar
• Hilven K, Patsopoulos NA, Dubois B, et al. Burden of risk variants correlates with phenotype of multiple sclerosis. Mult Scler J. 2015;21:1670–1680.
   PubMed Web of Science ®Google Scholar
• Mahad DH, Trapp BD, Lassmann H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. 2015;14:183–93.
   PubMedGoogle Scholar
• Schuh C, Wimmer I, Hametner S, et al. Oxidative tissue injury in multiple sclerosis is only partly reflected in experimental disease models. Acta Neuropathol. 2014;128:247–266.
   PubMed Web of Science ®Google Scholar
• Praet J, Guglielmetti C, Berneman Z, et al. Cellular and molecular neuropathology of the cuprizone mouse model: clinical relevance for multiple sclerosis. Neurosci Biobehav Rev. 2014; 47:485–505.
   PubMed Web of Science ®Google Scholar
• Khan O. Can clinical outcomes be used to detect neuroprotection in multiple sclerosis? Neurology. 2007;68:S64–S71.
   PubMed Web of Science ®Google Scholar
• Tur C, Moccia M, Barkhof F, et al. Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting. Nat Rev Neurol. 2018. DOI:10.1038/nrneurol.2017.171.
   PubMed Web of Science ®Google Scholar
• Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444–1452.
   PubMed Web of Science ®Google Scholar
• Meyer-Moock S, Feng YS, Maeurer M, et al. Systematic literature review and validity evaluation of the expanded disability status scale (EDSS) and the multiple sclerosis functional composite (MSFC) in patients with multiple sclerosis. BMC Neurol. 2014;14:58.
   PubMed Web of Science ®Google Scholar
• Fisk JD, Doble SE. Construction and validation of a fatigue impact scale for daily administration (D-FIS). Qual Life Res. 2002;11:263–272.
   PubMed Web of Science ®Google Scholar
• Fisk JD, Ritvo PG, Ross L, et al. Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin Infect Dis. 1994;18(Suppl 1):S79–83.
   PubMed Web of Science ®Google Scholar
• Ware JE Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473–483.
   PubMed Web of Science ®Google Scholar
• Hays R, Sherbourne CD, Mazel R. User’s manual for the medical outcomes Study (MOS) core measures of health-related quality of life (RAND corporation). Santa Monica, CA; 1995.
   Google Scholar
• Smith SM, Rao A, De Stefano N, et al. Longitudinal and cross-sectional analysis of atrophy in Alzheimer’s disease: cross-validation of BSI, SIENA and SIENAX. Neuroimage. 2007;36:1200–1206.
   PubMed Web of Science ®Google Scholar
• Barkhof F. MRI in multiple sclerosis: correlation with expanded disability status scale (EDSS). Mult Scler. 1999;5:283–286.
   PubMed Web of Science ®Google Scholar
• Van Waesberghe JH, Kamphorst W, De Groot CJ, et al. Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol. 1999;46:747–54.
   PubMedGoogle Scholar
• Zipp F. A new window in multiple sclerosis pathology: non-conventional quantitative magnetic resonance imaging outcomes. J Neurol Sci. 2009;287(Suppl 1):S24–9.
   PubMedGoogle Scholar
• Thaler C, Faizy T, Sedlacik J, et al. T1- thresholds in black holes increase clinical-radiological correlation in multiple sclerosis patients. PLoS One. 2015;10:e0144693.
   PubMed Web of Science ®Google Scholar
• Bovis F, De Stefano N, Steinerman JR, et al. Validating the use of brain volume cutoffs to identify clinically relevant atrophy in RRMS. Mult Scler J. 2017. DOI:10.1177/1352458517743804.
   PubMed Web of Science ®Google Scholar
• Audoin B, Ranjeva JP, Au Duong MV, et al. Voxel-based analysis of MTR images: a method to locate gray matter abnormalities in patients at the earliest stage of multiple sclerosis. J Magn Reson Imaging. 2004;20:765–771.
   PubMed Web of Science ®Google Scholar
• Bevan C, Cree B. Disease activity free status a new end point for a new era in multiple sclerosis clinical research? JAMA Neurol. 2014;71:269–270.
   PubMed Web of Science ®Google Scholar
• Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the natalizumab safety and efficacy in relapsing-remitting multiple sclerosis (AFFIRM) study. Lancet Neurol. 2009;8:254–260.
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Cook S, Rammohan K, et al. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. Lancet Neurol. 2011;10:329–337.
   PubMed Web of Science ®Google Scholar
• Kappos L, De Stefano N, Freedman M, et al. Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing-remitting multiple sclerosis. Mult Scler J. 2016;22:1297–1305.
   PubMed Web of Science ®Google Scholar
• Damasceno A, Damasceno BP, Cendes F. No evidence of disease activity in multiple sclerosis: implications on cognition and brain atrophy. Mult Scler J. 2016;22:64–72.
   PubMed Web of Science ®Google Scholar
• Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain. 1999;122(Pt 5):871–882.
   PubMed Web of Science ®Google Scholar
• Cohen JA, Cutter GR, Fischer JS, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology. 2002;59:679–687.
   PubMed Web of Science ®Google Scholar
• Disanto G, Barro C, Benkert P, et al. Serum neurofilament light: A biomarker of neuronal damage in multiple sclerosis. Ann Neurol. 2017;81:857–870.
   PubMed Web of Science ®Google Scholar
• Kuhle J, Barro C, Disanto G, et al. Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity. Mult Scler J. 2016;22:1550–1559.
   PubMed Web of Science ®Google Scholar
• Kuhle J, Nourbakhsh B, Grant D, et al. Serum neurofilament is associated with progression of brain atrophy and disability in early MS. Neurology. 2017;88:826–831.
   PubMed Web of Science ®Google Scholar
• Sormani MP, Haring DA, Kropshofer H, et al. Blood NfL as a potential endpoint in phase 2 clinical studies in relapsing-remitting multiple sclerosis. Mult Scler J. 2017;23:978–979.
   Google Scholar
• Birkeldh U, Manouchehrinia A, Hietala MA, et al. The temporal retinal nerve fiber layer thickness is the most important optical coherence tomography estimate in multiple sclerosis. Front Neurol. 2017;8:675.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. (2016) http://www.ema.europa.eu/ema/
   Google Scholar
• US Food and Drug Administration. (2016) http://www.fda.gov/
   Google Scholar
• Montalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler J. 2018. DOI:10.1177/1352458517751049.
   PubMedGoogle Scholar
• Kappos L, Gold R, Miller DH, et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet. 2008;372:1463–1472.
   PubMed Web of Science ®Google Scholar
• Comi G, O’Connor P, Montalban X, et al. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler J. 2010;16:197–207.
   PubMed Web of Science ®Google Scholar
• Montalban X, Comi G, O’Connor P, et al. Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II study. Mult Scler J. 2011;17:1341–1350.
   PubMed Web of Science ®Google Scholar
• Montalban X, Comi G, Antel J, et al. Long-term results from a phase 2 extension study of fingolimod at high and approved dose in relapsing multiple sclerosis. J Neurol. 2015;262:2627–2634.
   PubMed Web of Science ®Google Scholar
• Khatri BO, Pelletier J, Kappos L, et al. Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon beta-1a intramuscular: subgroup analyses of the trial assessing injectable interferon vs. fingolimod oral in relapsing-remitting multiple sclerosis (TRANSFORMS). Mult Scler Relat Disord. 2014;3:355–363.
   PubMed Web of Science ®Google Scholar
• Cohen JA, Khatri B, Barkhof F, et al. Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. J Neurol Neurosurg Psychiatry. 2016;87:468–475.
   PubMed Web of Science ®Google Scholar
• O’Connor PW, Li D, Freedman MS, et al. A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology. 2006;66:894–900.
   Google Scholar
• Confavreux C, Li DK, Freedman MS, et al. Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. Mult Scler J. 2012;18:1278–1289.
   PubMed Web of Science ®Google Scholar
• Vermersch P, Czlonkowska A, Grimaldi LM, et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult Scler J. 2014;20:705–716.
   PubMed Web of Science ®Google Scholar
• Gold R, Giovannoni G, Phillips JT, et al. Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS). Mult Scler J. 2015;21:57–66.
   PubMedGoogle Scholar
• Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367:1098–1107.
   PubMed Web of Science ®Google Scholar
• Bar-Or A, Gold R, Kappos L, et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study. J Neurol. 2013;260:2297–2305.
   PubMed Web of Science ®Google Scholar
• Arnold DL, Gold R, Kappos L, et al. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 DEFINE study. J Neurol. 2014;261:1794–1802.
   PubMed Web of Science ®Google Scholar
• Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367:1087–1097.
   PubMed Web of Science ®Google Scholar
• Hutchinson M, Fox RJ, Miller DH, et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study. J Neurol. 2013;260:2286–2296.
   PubMed Web of Science ®Google Scholar
• Miller DH, Fox RJ, Phillips JT, et al. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. Neurology. 2015;84:1145–1152.
   PubMed Web of Science ®Google Scholar
• Viglietta V, Miller D, Bar-Or A, et al. Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials. Ann Clin Transl Neurol. 2015;2:103–118.
   PubMed Web of Science ®Google Scholar
• Chun J, Brinkmann V. A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya). Discov Med. 2011;12:213–228.
   PubMed Web of Science ®Google Scholar
• Kim S, Bielawski J, Yang H, et al. Functional antagonism of sphingosine-1-phosphate receptor 1 prevents cuprizone-induced demyelination. Glia. 2018;66:654–669.
   PubMed Web of Science ®Google Scholar
• Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006;355:1124–1140.
   PubMed Web of Science ®Google Scholar
• Kappos L, Radue EW, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362:387–401.
   PubMed Web of Science ®Google Scholar
• Calabresi PA, Radue EW, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13:545–556.
   PubMed Web of Science ®Google Scholar
• Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362:402–415.
   PubMed Web of Science ®Google Scholar
• Kappos L, O’Connor P, Radue EW, et al. Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial. Neurology. 2015;84:1582–1591.
   PubMed Web of Science ®Google Scholar
• Sormani MP, De Stefano N, Francis G, et al. Fingolimod effect on brain volume loss independently contributes to its effect on disability. Mult Scler J. 2015;21:916–924.
   PubMed Web of Science ®Google Scholar
• Khatri B, Barkhof F, Comi G, et al. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol. 2011;10:520–529.
   PubMed Web of Science ®Google Scholar
• Cohen JA, Barkhof F, Comi G, et al. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. J Neurol. 2013;260:2023–2032.
   PubMed Web of Science ®Google Scholar
• Lublin F, Miller DH, Freedman MS, et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387:1075–1084.
   PubMed Web of Science ®Google Scholar
• Cohen JA, Arnold DL, Comi G, et al. Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2016;15:373–381.
   PubMed Web of Science ®Google Scholar
• Arnold DL, Cohen JA, Comi G, et al. Ozanimod demonstrates preservation of brain volume at 1 and 2 years in two phase 3 trials of relapsing multiple sclerosis (SUNBEAM and RADIANCE). Mult Scler J. 2017;23:986–987.
   Google Scholar
• Fox R, Arnold DL, Bar-Or A, et al. Effects of siponimod on MRI outcomes in patients with secondary progressive multiple sclerosis: results of the phase 3 EXPAND study. Mult Scler J. 2017;23:34–35.
   PubMed Web of Science ®Google Scholar
• Kappos L, Vermersch P, Bar-Or A, et al. Efficacy of siponimod on disability progression in SPMS patients with and without on-study relapses. Mult Scler J. 2017;23:397–398.
   Google Scholar
• O’Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365:1293–1303.
   Google Scholar
• Wolinsky JS, Narayana PA, Nelson F, et al. Magnetic resonance imaging outcomes from a phase III trial of teriflunomide. Mult Scler J. 2013;19:1310–1319.
   Google Scholar
• Miller AE, O’Connor P, Wolinsky JS, et al. Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Mult Scler J. 2012;18:1625–1632.
   PubMed Web of Science ®Google Scholar
• O’Connor P, Comi G, Freedman MS, et al. Long-term safety and efficacy of teriflunomide: nine-year follow-up of the randomized TEMSO study. Neurology. 2016;86:920–930.
   PubMed Web of Science ®Google Scholar
• Confavreux C, O’Connor P, Comi G, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13:247–256.
   PubMed Web of Science ®Google Scholar
• Freedman MS, Wolinsky JS, Comi G, et al. The efficacy of teriflunomide in patients who received prior disease-modifying treatments: subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies. Mult Scler J. 2017. DOI:10.1177/1352458517695468.
   Google Scholar
• Leist TP, Weissert R. Cladribine: mode of action and implications for treatment of multiple sclerosis. Clin Neuropharmacol. 2011;34:28–35.
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362:416–426.
   PubMed Web of Science ®Google Scholar
• Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012;380:1819–1828.
   PubMed Web of Science ®Google Scholar
• Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380:1829–1839.
   PubMed Web of Science ®Google Scholar
• Coles AJ, Compston DA, Selmaj KW, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008;359:1786–1801.
   PubMed Web of Science ®Google Scholar
• Coles AJ, Fox E, Vladic A, et al. Alemtuzumab more effective than interferon beta-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology. 2012;78:1069–1078.
   PubMed Web of Science ®Google Scholar
• Tuohy O, Costelloe L, Hill-Cawthorne G, et al. Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy. J Neurol Neurosurg Psychiatry. 2015;86:208–215.
   PubMed Web of Science ®Google Scholar
• Kalincik T, Brown J, Robertson N, et al. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. Lancet Neurol. 2017;16:271–281.
   PubMed Web of Science ®Google Scholar
• Wynn D, Kaufman M, Montalban X, et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol. 2010;9:381–390.
   PubMed Web of Science ®Google Scholar
• Gold R, Giovannoni G, Selmaj K, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet. 2013;381:2167–2175).
   PubMed Web of Science ®Google Scholar
• Hobart J, Lamping D, Fitzpatrick R, et al. The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. Brain. 2001;124:962–973.
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Gold R, Selmaj K, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial. Lancet Neurol. 2014;13:472–481.
   PubMed Web of Science ®Google Scholar
• Gold R, Radue EW, Giovannoni G, et al. Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study. BMC Neurol. 2016;16:117.
   PubMed Web of Science ®Google Scholar
• Kappos L, Wiendl H, Selmaj K, et al. Daclizumab HYP versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2015;373:1418–1428.
   PubMed Web of Science ®Google Scholar
• Krueger JG, Kircik L, Hougeir F, et al. Cutaneous adverse events in the randomized, double-blind, active-comparator DECIDE study of daclizumab high-yield process versus intramuscular interferon beta-1a in relapsing-remitting multiple sclerosis. Adv Ther. 2016;33:1231–1245.
   PubMed Web of Science ®Google Scholar
• Liu Y, Vollmer T, Havrdova E, et al. Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2017;11:18–24.
   PubMed Web of Science ®Google Scholar
• Li DCalabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet. 2011;378:1779–1787.
   PubMed Web of Science ®Google Scholar
• Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376:221–234.
   PubMed Web of Science ®Google Scholar
• Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017; 376:209–220.
   PubMed Web of Science ®Google Scholar
• Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358:676–688.
   PubMed Web of Science ®Google Scholar
• Hawker K, O’Connor P, Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009;66:460–471.
   PubMed Web of Science ®Google Scholar
• Mi S, Pepinsky RB, Cadavid D. Blocking LINGO-1 as a therapy to promote CNS repair: from concept to the clinic. CNS Drugs. 2013;27:493–503.
   PubMed Web of Science ®Google Scholar
• Gresle MM, Liu Y, Kilpatrick TJ, et al. Blocking LINGO-1 in vivo reduces degeneration and enhances regeneration of the optic nerve. Mult Scler J Exp Transl Clin. 2016;2:2055217316641704.
   Google Scholar
• Mi S, Hu B, Hahm K, et al. LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nat Med. 2007;13:1228–1233.
   PubMed Web of Science ®Google Scholar
• Cadavid D, Balcer L, Galetta S, et al. Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2017;16:189–199.
   PubMed Web of Science ®Google Scholar
• Blinkenberg M, Soelberg Sorensen P. Monoclonal antibodies for relapsing multiple sclerosis: a review of recently marketed and late-stage agents. CNS Drugs. 2017;31:357–371.
   PubMed Web of Science ®Google Scholar
• Bruck W, Wegner C. Insight into the mechanism of laquinimod action. J Neurol Sci. 2011;306:173–179.
   PubMed Web of Science ®Google Scholar
• Comi G, Jeffery D, Kappos L, et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med. 2012;366:1000–1009.
   PubMed Web of Science ®Google Scholar
• Filippi M, Rocca MA, Pagani E, et al. Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. J Neurol Neurosurg Psychiatry. 2014;85:851–858.
   PubMed Web of Science ®Google Scholar
• Vollmer TL, Sorensen PS, Selmaj K, et al. A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. J Neurol. 2014;261:773–783.
   PubMed Web of Science ®Google Scholar
• Comi G, Vollmer TL, Boyko A, et al. CONCERTO: a placebo-controlled trial of oral laquinimod in patients with relapsing-remitting multiple sclerosis. Mult Scler J. 2017;23:74–75.
   Google Scholar
• Sargin D, Friedrichs H, El-Kordi A, et al. Erythropoietin as neuroprotective and neuroregenerative treatment strategy: comprehensive overview of 12 years of preclinical and clinical research. Best Pract Res Clin Anaesthesiol. 2010;24:573–594.
   PubMedGoogle Scholar
• Diem R, Sattler MB, Merkler D, et al. Combined therapy with methylprednisolone and erythropoietin in a model of multiple sclerosis. Brain. 2005;128:375–385.
   PubMed Web of Science ®Google Scholar
• Zhang J, Li Y, Cui Y, et al. Erythropoietin treatment improves neurological functional recovery in EAE mice. Brain Res. 2005;1034:34–39.
   PubMed Web of Science ®Google Scholar
• Ehrenreich H, Hinze-Selch D, Stawicki S, et al. Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin. Mol Psychiatry. 2007;12:206–220.
   PubMed Web of Science ®Google Scholar
• Tseng MY, Hutchinson PJ, Richards HK, et al. Acute systemic erythropoietin therapy to reduce delayed ischemic deficits following aneurysmal subarachnoid hemorrhage: a phase II randomized, double-blind, placebo-controlled trial. Clinical Article J Neurosurg. 2009;111:171–180.
   Google Scholar
• Neubauer AP, Voss W, Wachtendorf M, et al. Erythropoietin improves neurodevelopmental outcome of extremely preterm infants. Ann Neurol. 2010;67:657–666.
   PubMed Web of Science ®Google Scholar
• Ehrenreich H, Fischer B, Norra C, et al. Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. Brain. 2007;130:2577–2588.
   PubMed Web of Science ®Google Scholar
• Suhs KW, Hein K, Sattler MB, et al. A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis. Ann Neurol. 2012;72:199–210.
   PubMed Web of Science ®Google Scholar
• Shayegannejad V, Shahzamani S, Dehghani A, et al. A double-blind, placebo-controlled trial of adding erythropoietin to intravenous methylprednisolone for the treatment of unilateral acute optic neuritis of unknown or demyelinative origin. Graefes Arch Clin Exp Ophthalmol. 2015;253:797–801.
   PubMed Web of Science ®Google Scholar
• Cho Y, Crichlow GV, Vermeire JJ, et al. Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast. Proc Natl Acad Sci U S A. 2010;107:11313–11318.
   Google Scholar
• Chen RW, Williams AJ, Liao Z, et al. Broad spectrum neuroprotection profile of phosphodiesterase inhibitors as related to modulation of cell-cycle elements and caspase-3 activation. Neurosci Lett. 2007;418:165–169.
   PubMed Web of Science ®Google Scholar
• Nakamizo T, Kawamata J, Yoshida K, et al. Phosphodiesterase inhibitors are neuroprotective to cultured spinal motor neurons. J Neurosci Res. 2003;71:485–495.
   PubMed Web of Science ®Google Scholar
• Barkhof F, Hulst HE, Drulovic J, et al. Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant? Neurology. 2010;74:1033–1040.
   PubMed Web of Science ®Google Scholar
• Fox RJ, Coffey CS, Cudkowicz ME, et al. SPRINT-MS/NN 102 phase II trial of ibudilast in progressive MS: top-line results. Mult Scler J. 2017;23:979–980.
   Web of Science ®Google Scholar
• Kapoor R, Furby J, Hayton T, et al. Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Neurol. 2010;9:681–688.
   PubMed Web of Science ®Google Scholar
• Sedel F, Bernard D, Mock DM, et al. Targeting demyelination and virtual hypoxia with high-dose biotin as a treatment for progressive multiple sclerosis. Neuropharmacology. 2016;110:644–653.
   PubMed Web of Science ®Google Scholar
• Eleuteri C, Olla S, Veroni C, et al. A staged screening of registered drugs highlights remyelinating drug candidates for clinical trials. Sci Rep. 2017;7:45780.
   PubMed Web of Science ®Google Scholar
• Farjam M, Zhang GX, Ciric B, et al. Emerging immunopharmacological targets in multiple sclerosis. J Neurol Sci. 2015;358:22–30.
   PubMed Web of Science ®Google Scholar
• Shirani A, Okuda DT, Stuve O. Therapeutic advances and future prospects in progressive forms of multiple sclerosis. Neurotherapeutics. 2016;13:58–69).
   PubMed Web of Science ®Google Scholar
• Wiendl H, Hohlfeld R. Therapeutic approaches in multiple sclerosis – lessons from failed and interrupted treatment trials. Biodrugs. 2002;16:183–200.
   PubMed Web of Science ®Google Scholar
• Zivadinov R, Weinstock-Guttman B, Hashmi K, et al. Smoking is associated with increased lesion volumes and brain atrophy in multiple sclerosis. Neurology. 2009;73:504–510.
   PubMed Web of Science ®Google Scholar
• Ramanujam R, Hedstrom AK, Manouchehrinia A, et al. Effect of smoking cessation on multiple sclerosis prognosis. JAMA Neurol. 2015;72:1117–1123.
   PubMed Web of Science ®Google Scholar
• Graetz C, Gröger A, Salmen A, et al. Association of smoking but not HLA-DRB1*15:01, APOE or body mass index with brain atrophy in early multiple sclerosis. Mult Scler J. 2018 in press
   Google Scholar